Latest Shareholder Activism News

The Takeovers Panel has declined to investigate applications challenging Pact Group Holdings’ proposed delisting, signaling regulatory acceptance of the move. The decision clarifies the Panel’s jurisdiction and leaves the delisting process on track.

A shareholder has lodged a formal application with the Takeovers Panel challenging FBR Limited’s recent share placements and governance practices, raising concerns over disclosure and shareholder engagement.

Almonty Industries reported a sharp increase in net loss for Q1 2025 despite stable revenues, driven by significant non-cash charges on warrant and derivative liabilities. The company secured additional financing to support ongoing operations and project development.

A significant shareholder has lodged an application with the Takeovers Panel challenging Pact Group Holdings’ proposed delisting from the ASX, alleging misleading reasons and coercion of minority investors.

Southern Cross Media Group rebuffs Sandon Capital’s attempt to remove four directors, backed by majority shareholders and buoyed by strong operational momentum.

An application to the Takeovers Panel challenges Pact Group Holdings’ planned ASX delisting, citing concerns over shareholder disadvantage and selective disclosure.

NZME Limited has received eight director nominations from major shareholders ahead of its June 2025 Annual Shareholders’ Meeting, prompting the Board to propose an alternative composition focused on digital transformation and governance stability.

Pact Group Holdings has received conditional approval from the ASX for its voluntary delisting, pending shareholder endorsement at an upcoming extraordinary general meeting scheduled for 12 June 2025.

EMU NL’s latest quarterly report reveals promising copper exploration parallels with Canada’s largest open-pit mine, a renewed gold project strategy, and significant corporate restructuring amid shareholder disputes.

EMU NL's latest quarterly report reveals promising copper exploration parallels with Canada’s Highland Valley mine and renewed gold project interest, alongside significant management changes and a pending shareholder showdown.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Clara Resources outlines key progress on its Ashford Coking Coal Project drilling preparations and details ongoing capital management initiatives, including rights issues and entitlement offers, while navigating boardroom challenges.